{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=axicabtagene+ciloleucel&page=2",
    "query": {
      "intervention": "axicabtagene ciloleucel",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 45,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=axicabtagene+ciloleucel&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=axicabtagene+ciloleucel&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T00:33:01.271Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03105336",
      "title": "A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Indolent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Axicabtagene ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2017-06-06",
      "completion_date": "2024-12-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 17,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03105336"
    },
    {
      "nct_id": "NCT03153462",
      "title": "Axicabtagene Ciloleucel Expanded Access Study",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B Cell Lymphoma",
        "Relapsed/Refractory Primary Mediastinal B Cell Lymphoma",
        "Relapsed/Refractory Transformed Follicular Lymphoma",
        "Relapsed/Refractory High-Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Stanford, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03153462"
    },
    {
      "nct_id": "NCT07188558",
      "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "Lymphoma, B-Cell",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma Refractory/ Relapsed",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Diffuse Large B Cell Lymphoma Refractory",
        "Diffuse Large B Cell Lymphoma Relapsed"
      ],
      "interventions": [
        {
          "name": "rondecabtagene autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "axicabtagene ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "lisocabtagene maraleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2026-01-12",
      "completion_date": "2032-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 36,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07188558"
    },
    {
      "nct_id": "NCT05349201",
      "title": "CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Acute Lymphoblastic Leukemia (ALL)"
      ],
      "interventions": [
        {
          "name": "KYMRIAH",
          "type": "OTHER"
        },
        {
          "name": "YESCARTA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 273,
      "start_date": "2020-12-09",
      "completion_date": "2021-05-28",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05349201"
    },
    {
      "nct_id": "NCT06271369",
      "title": "Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2022-08-11",
      "completion_date": "2023-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-21",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06271369"
    },
    {
      "nct_id": "NCT04432506",
      "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-07-27",
      "completion_date": "2024-05-28",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432506"
    },
    {
      "nct_id": "NCT03761056",
      "title": "Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2019-01-29",
      "completion_date": "2023-10-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 5,
      "location_summary": "Gilbert, Arizona • Duarte, California • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761056"
    },
    {
      "nct_id": "NCT02601313",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "brexucabtagene autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2015-11-09",
      "completion_date": "2023-09-22",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Duarte, California • Santa Monica, California + 20 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601313"
    },
    {
      "nct_id": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum-containing Salvage Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 359,
      "start_date": "2018-01-25",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03391466"
    },
    {
      "nct_id": "NCT07763210",
      "title": "Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Therapeutic Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brexucabtagene Autoleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2026-09-25",
      "completion_date": "2029-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-07T00:33:01.271Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07763210"
    }
  ]
}